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Abstract
Background: The risk of cardiovascular events remains high in patients with coronary heart disease (CHD) after
successful percutaneous coronary intervention (PCI). Panax quinquefolius saponin, a major component of Xinyue
capsule, has been used to treat patients with CHD. The aim of this study is to evaluate the efficacy and safety of
Xinyue capsules in patients with CHD after PCI.
Methods/design: This study is a multicenter, placebo-controlled, double-blind, randomized controlled clinical trial.
A total of 1100 participants are randomly allocated to two groups: the intervention group and a placebo group.
The intervention group receives Xinyue capsules plus conventional treatment, and the placebo group receives
placebo capsules plus conventional treatment. The patients receive either Xinyue or placebo capsules three times
daily (1.8 g/day) for up to 24 weeks. The primary outcome measure is the time from randomization to the first
occurrence of major adverse cardiovascular events. The secondary outcome measure is the time from randomization
to the first occurrence of stroke, pulmonary embolism, and peripheral vascular events, as well as death due to any
cause. All outcome measures will be assessed at 12, 24, 36, and 48 weeks after randomization. Adverse events will be
monitored during the trial.
Discussion: The aim of this study is to evaluate the effects of Xinyue capsules on patients with CHD after
interventional treatment. The results of this trial will provide critical evidence regarding Chinese herbal medicine
treatment for CHD.
Trial registration: Chinese Clinical Trials Registry identifier ChiCTR-IPR-14005475. Registered on 10 November 2014.
Keywords: Xinyue capsule, Coronary heart disease, Randomized controlled trial
Background
Percutaneous coronary intervention (PCI) is commonly
performed for coronary revascularization in patients
with stable angina or acute coronary syndrome (ACS)
[1]. Nevertheless, there are several medications with
proven benefit to patients with cardiovascular disease,
such as dual-antiplatelet therapy, statins, β-blockers, and
angiotensin-converting enzyme inhibitors [2]. Unfortunately,
the risk of cardiovascular events remains high in patients
after PCI [3]. Many patients do not receive the conventional
treatment due to the side effects, contraindications, and
drug-drug interactions [4]. Selecting the optimal clinical
strategies to prevent the occurrence of cardiovascular events
is challenging.
Traditional Chinese medicine (TCM) has been used
to treat coronary heart disease (CHD) for thousands
of years [5]. From the perspective of TCM, patients
with CHD can be divided into different syndromes
(i.e., different zhengs). In the diagnosis of CHD, the
“Qi and Yin inadequacy syndrome” is the important
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subtype. In 2005, Xinyue capsules were approved by
the China Food and Drug Administration for treat-
ment of CHD. The main component of Xinyue
capsules—Panax quinquefolius saponin (PQS)—is ex-
tracted from the stem and leaves of Panax quinquefo-
lium, which in TCM theory could reinforce Qi and
nourish Yin. Previous studies have shown that PQS
has various pharmacological actions, including anti-
myocardial cell damage [6], protection of heart function,
reduction of myocardial oxygen consumption [7, 8], im-
provement of myocardial perfusion [9] and ventricular re-
modeling after acute myocardial infarction (MI) [10],
antiapoptosis of ischemic myocardial cells [11, 12], regula-
tion of glucose and lipid metabolism [13], and improve-
ment of insulin resistance [14, 15]. A multicenter
randomized clinical study [16] showed that the combin-
ation of Xinyue capsules with Chuanxiong capsules and
conventional Western interventions could reduce the
occurrence of cardiovascular events in patients with ACS
after PCI without increasing the risk of major bleeding.
The results of pharmaceutical chemistry and pharmaco-
kinetics conducted jointly by Xiyuan Hospital and Medical
University of Vienna showed that the fingerprint of
Xinyue capsules from different batches or the same batch
at different time points was consistent, and the measure-
ments of heavy metal and pesticide residues were within
European Union standards.
Based on the multifactorial effect on CHD of Xiyue
capsule, our hypothesis is that Xiyue capsules plus
conventional treatment can improve cardiovascular out-
comes in patients with CHD after interventional treat-
ment compared with conventional treatment alone. If
successful, it will provide a novel, promising alternative
strategy for further reducing cardiovascular events.
Methods/design
Study design
This study is registered in the Chinese Clinical Trials
Registry (ChiCTR-IPR-14005475). It is a multicenter,
double-blind, randomized, placebo-controlled clinical
trial. This study complies with the principles of the
Declaration of Helsinki and Good Clinical Practice
guidelines. Written informed consent will be obtained
from all patients prior to their participation in this study,
and the recruited patients will be randomized to either
the Xiyue capsule group or the placebo group. We
will rigorously follow the Consolidated Standards of
Reporting Trials (CONSORT) recommendations in
reporting the results [17].
The trial will be conducted in 25 centers in China (see
in Additional file 1). A total of 1100 participants will be
recruited. After acquiring consent from the participants
or their parents and/or legal guardians, the participants
will be enrolled in the trial, which consists of a 1-week
run-in period, a 24-week treatment period, and a 24-
week follow-up period. An outline of the study proce-
dures is illustrated in Fig. 1.
Fig. 1 Study flowchart. QOLQ Quality of Life Questionnaire, SF-36 36-item Short Form Health Survey, TCM traditional Chinese medicine
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Participants
Inpatients and outpatients in the participating centers
will be screened if they meet the selection criteria.
Inclusion criteria
1. CHD was diagnosed according to the guidelines
[2, 18]. All participants must have received
successful PCI.
2. The time window is within 1 year after PCI and the
patient must be clinically stable, defined as follows:
a. No progressive chest pain is present.
b. The troponin value is within normal range or
slightly elevated, but lower than the 99th
percentile of the upper reference limit value.
c. The participants must have a Canadian
Cardiovascular Society classification of angina I
to II
3. Patients are diagnosed as having a syndrome of
deficiency of both Qi and Yin according to TCM
standards [19].
4. Patients must be aged 18–75 years.
5. Patients must have a New York Heart Association
cardiac functional class I–II
6. Patients are informed about the trial and voluntarily
sign the consent form.
Exclusion criteria
1. Renal insufficiency, male serum creatinine >2.5 mg/
dl (>220 μmol/L), female serum creatinine >2.0 mg/
dl (>175 μmol/L)
2. Serious liver disease or alanine transaminase and
aspartate transaminase values two times higher than
the upper reference limit value
3. Systolic blood pressure >160 mmHg or diastolic
blood pressure >100 mmHg
4. Presence of diabetes with random blood glucose
level ≥13.7 mmol/L or HbA1c ≥9.5 %
5. Pregnant women or women who are preparing for
pregnancy, and subjects who are known to be
allergic to ingredients of the study drug
6. Acute cerebrovascular disease
7. Malignancy or having a life expectancy less than
3 years
8. Severe hematopoietic diseases
9. Severe psychiatric conditions
10. Previous involvement in other clinical trials or
participation in other clinical trials within the past
3 months
Withdrawal, dropout, and discontinuation
Participants can voluntarily withdraw at any time during
the trial. Subjects who meet the inclusion criteria, fill
out and sign the consent form, and successfully enter
the randomized trial who fail to complete the observa-
tional period proposed in the trial, regardless of time
and reasons, are considered as dropout cases. Reasons
for withdrawal will be recorded in case report forms
(CRFs), and the last data recorded for these participants
will be included in the data analysis.
The trial can be terminated in the following circum-
stances: (1) occurrence of serious adverse events (AEs)
related to the research medication, (2) the test drug is
found to have no clinical value during the trial, (3) finan-
cial and management reasons, and/or (4) administrative
authorities terminate the trial.
Intervention
Eligible patients will be allocated to receive Xinyue
capsule or placebo for 6 months in addition to conven-
tional treatment, including antiplatelet, lipid-lowering,
antihypertensive, or antidiabetic therapy, according to
the clinical guidelines. The Xinyue capsules and placebo
capsules (0.6 g ante cibum, three times daily for
24 weeks; China State Food and Drug Administration
approval number Z20030073) will be provided by Jilin
Jilin Jian Yisheng Pharmaceutical Co. Ltd. (Ji’An City,
China). Each capsule is 0.3 g, equivalent to 50 mg of P.
quinquefolium saponin. The Xinyue and placebo cap-
sules have the same outer packaging, color, shape, and
flavor.
Outcomes and measures
The primary outcome is the time from randomization
to the first occurrence of the major adverse cardio-
vascular event (MACE): cardiac death (any death un-
less an unequivocal noncardiac cause could be
established), nonfatal MI (appearance of pathological
Q waves that were absent at baseline or a total creat-
ine kinase [CK] level more than two times the upper
limit of normal [ULN] with presence of CK isoen-
zyme MB higher than the ULN), and urgent
revascularization with either PCI or coronary artery
bypass graft. The secondary outcome measures is the
time from randomization to the first occurrence of,
stroke, pulmonary embolism, and peripheral vascular
events, as well as death due to any cause. Safety out-
comes, which include a complete blood count, kidney
and liver function tests, high-sensitivity C-reactive
protein level, cardiac function index, blood lipid
levels, Quality of Life Questionnaire (QLQ) score, 36-
item Short Form Health Survey (SF-36) score, and
TCM syndrome score will also be monitored periodic-
ally. All AEs will be followed from randomization to
the end of the trial. Items to be measured and the
time window of data collection are shown in Table 1.
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Adverse events
AEs are defined as negative or unintended clinical mani-
festations following the treatment. Patients will be asked
to report to the investigators any abnormal reactions oc-
curring at any time during the trial. In addition, investi-
gators will collect information about abnormal reactions
monthly. All details of related and unexpected AEs, such
as time of occurrence, degree of AE, and suspected
causes, will be recorded on CRFs. There is also a data
safety monitoring board to oversee the trial.
Study-specific visits and procedures
The schedule for all study-related procedures for all
evaluations is shown in Table 1. For each procedure,
subjects are to be assessed by the same investigator or
site personnel whenever possible. The timing of each
visit is relative to randomization (day 1). Baseline
measures include demographic characteristics, medical
history, medications, measurement of vital signs
(temperature, blood pressure, breathing and heart rates),
complete blood count, routine urine test, stool test, liver
and kidney function tests, 12-lead electrocardiogram,
cardiac ultrasound, TCM syndrome, and QLQ and SF-
36 scores (details in the Additional file 2). All baseline
measurements excluding the medical history will be re-
peated with all participants at visit 4 and visit 6. The
TCM syndrome, QLQ, and SF-36 data will be recorded
at visit 3 and visit 5. AEs and outcome measurements
will be recorded from visit 3 to visit 6.
Randomization and blinding
Participants are randomized in a 1:1 ratio using a
computer-generated, site-stratified, block randomization
schedule. The study capsule will be labeled with sequen-
tial randomization numbers, and each patient will be
assigned the lowest number available at each participating
Table 1 Measurement items and points of data capture
Screening Treatment period Follow-up period















Tongue and pulse condition in TCM X X X X X X
Vital signs X X X X X X
12-lead ECG X X X
Complete blood count, urine
and stool tests
X X X
Liver and renal function tests X X X
Coagulation function test X X X
Adverse event evaluation X X X X
Dispense drug X X X X X
Primary endpoint X X X X
Secondary endpoint X X X X
Cardiac function X X X
hs-CRP X X X
Lipid panels X X X
QLR score X X X X X
SF-36 score X X X X X
TCM syndrome score X X X X X
Abbreviations: ECG electrocardiogram, hs-CRP high-sensitivity C-reactive protein, SF36 36-item Short Form Health Survey, TCM traditional Chinese medicine, QLQ
quality of Life Questionnaire
X represents the indicators tested in the specific time period
Coagulation function test: prothrombin time, activated partial thromboplastin time, fibrinogen, thrombin time
Lipid panels: high-density lipoprotein, low-density lipoprotein, cholesterol, triglycerides
Primary endpoint: time from randomization to the first occurrence of the major adverse cardiovascular event
Secondary endpoint: time from randomization to the first occurrence of stroke, pulmonary embolism, and peripheral vascular events, as well as death due to any cause
Guo et al. Trials  (2016) 17:412 Page 4 of 7
center. All patients, care providers, and attending physi-
cians will be blinded to treatment assignment until the
study is completed. The duplicated blinding codes will be
given to the main research institution and the manufac-
turer to keep, and the blinding codes cannot be broken
during the trial.
Date entry and quality control of data
CRFs have been used for data entry, and data from all
participating centers will be imported into the clinical
data management system (http://www.xyedc.com/). To
maintain the quality of the data, we will adopt valid
measures to ensure information accuracy, integrity, and
authenticity. First, computer logic checks will be run to
identify items such as inconsistent dates, missing data,
and questionable values. After that, the supervisor will
perform source data verification to check the consistency of
the original data. Queries may be issued by the supervisor
and will be answered by the site investigators (see in the
additional file 3). Second, manual checks will identify more
complicated and less common errors. Third, the supervisor
will conduct the site visit to compare the electronic data-
base with the source documents. Identified errors will be
solved to ensure the data quality. Fourth, the Data Coordin-
ation Center will be in charge of data validation.
Sample size calculation
The sample size was calculated on the basis of expected
reduction in cardiovascular events (cardiac death, all-
cause mortality, reoccurrence of MI, and any form of
revascularization). A previous study suggested that the
incidence for all major clinical cardiovascular events
combined at 1 year after interventional treatment of
CHD is 12.8 % [20]. Therefore, the hypothesis of this
study is to reduce the incidence of cardiovascular events
to 7 % in the treatment group. Given a type I error rate
of α = 0.05, a power of 80 % (type II error rate of β = 0.2),
the sample size for one arm needs to be 447, resulting in
n = 2 × 447 = 894 patients. Considering a dropout rate of
20 %, a total of 1097 patients needs to be allocated to
reach the required number of patients for the efficacy ana-
lysis. For convenience of randomization, we decided to
recruit 1100 patients. The formula used to calculate the
sample size is as follows:







The data from all participating centers will be combined
for statistical analysis of the primary and secondary end-
points as well as AEs. The analysis will be done at
Beijing Jiaotong University. Continuous variables will be
presented as the mean ± SD. The comparability of the
characteristics between the two study groups will be
assessed using a two-samples Student’s t test for con-
tinuous variables and the χ2 test or Wilcoxon test, when
appropriate, for categorical variables. The Wilcoxon
paired signed-rank test will be used for within-group
comparisons.
All randomized patients constituted the intention-to-
treat population. All participants will be analyzed
according to their original treatment allocation. Primary
and secondary endpoint data will be collected for the
entire follow-up period for all patients. Patients lost to
follow-up will be considered at risk until the date of last
contact, at which point they will be censored. Kaplan--
Meier curves will be used to examine MACE-free sur-
vival time. The Cox proportional hazards model with
covariates of treatment will be used for primary and sec-
ondary analyses. Hazard ratios and 95 % confidence in-
tervals for each of the categories determined by age, sex,
diabetes, and conventional therapy will be provided for
the primary and secondary endpoints.
For all analyses, a value of P < 0.05 will be considered
statistically significant, and all tests will be two-tailed.
All analyses will be conducted using SAS software
version 9.2 (SAS Institute, Cary, NC, USA).
Discussion
In this trial, we will investigate whether the Xinyue cap-
sule combined with conventional treatment reduces the
incidence of MACE and improve quality of life among
patients within 1 year after PCI. With the pleiotropic
effects that encompass antioxidant, antiapoptosis, and im-
provement of insulin resistance, PQS was demonstrated to
modify regional endothelial function, decrease oxidative
stress and blood glucose, and induce angiogenesis [21–24].
In our previous studies, we have found that Xinyue
capsules plus Chuanxiong capsules combined with conven-
tional treatment can further reduce the incidence of
cardiovascular events without any adverse effect in patients
with ACS after PCI [16]. A small-sample clinical trial in
which researchers recruited 100 patients with ACS after
successful PCI showed that Xinyue capsules together with
Western medicine treatment can improve cardiac function
and quality of life [25]. These findings and observations
serve as an impetus for large controlled trials to examine
the effect of Xinyue capsules in patients with ACS after
successful PCI. The present study is designed as a
multicenter, double-blind, randomized, placebo-controlled,
parallel-group superiority trial that will provide higher-
powered evidence regarding long-term survival with the
use of Xinyue capsules in addition to conventional
treatment for patients with CHD after successful PCI.
Guo et al. Trials  (2016) 17:412 Page 5 of 7
Our study has some limitations. First, the study is
being undertaken in China, so it is uncertain whether
the relative effects of the trial drugs would be similar in
other ethnic groups. The relatively short follow-up
period is another limitation of the study.
To conclude, the aim of this trial is to demonstrate
that Xinyue capsules plus conventional treatment will
lead to a reduction in the incidence of MACE in patients
with CHD after successful PCI and subsequently yield
long-term benefit.
Trial status
The trial was initiated in December 2014 and is cur-
rently open for enrollment. A total of 452 participants
have been enrolled. However, no analysis has been con-
ducted since the commencement of the trial.
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